Journal article
Volatility of elevated serum ferritin in anemic hemodialysis patients
Journal of nephrology, v 22(4), pp 553-560
01 Jul 2009
PMID: 19662612
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: Value of serum ferritin (SF) as an iron store index in hemodialysis (HD) patients has been questioned, especially at ranges >= 200. The objective of this study was to determine the variability of SF in patients with high SF (500-1,200.) and low TSAT (<= 25%).
Methods: This was a multicenter observational study. Data were obtained from Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study voluntary subject screening surveys (n=96), which reported epoetin dose, pre-screening and screening hemoglobin, TSAT and SF. Entry criteria were age >= 18 years, HD >= 90 days, SF 500-1,200., TSAT <= 25%, hemoglobin <= 11 g/dL, epoetin >= 22,500 IU/week or >= 225 IU/kg/week and <= 125 mg i.v. iron/week in the 4 weeks prior to screening. Groups were stratified by intervals of time between laboratory dates: 1-14 days (group 1), 15-28 (group 2) and 29-42 (group 3). Changes from pre-screening to screening were evaluated.
Results: SF changes (Delta SF) in groups 1, 2 and 3 were -63. (range -414 to +415.; p=0.013), -191. (range -379 to +427.; p=0.001) and -144. (range -541 to +181.; p=0.018), respectively. Within group 1, proportions of patients experiencing an absolute Delta SF >= 100., >= 200. and >= 300. were 61.0%, 29.3% and 12.2%, respectively, and 27% exhibited positive changes in SF.
Conclusions: SF is a volatile and imprecise indicator of tissue iron stores in anemic HD patients with high SF and low TSAT. This volatility limits clinical utility of SF in this population.
Metrics
8 Record Views
Details
- Title
- Volatility of elevated serum ferritin in anemic hemodialysis patients
- Creators
- David J. Hobbs - Drexel Univ, Coll Med, Dept Med, Div Nephrol & Hypertens, Philadelphia, PA 19102 USAAllan B. Schwartz - Drexel Univ, Coll Med, Dept Med, Div Nephrol & Hypertens, Philadelphia, PA 19102 USAEd Gracely - Drexel UniversityToros Kapoian - Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USAAdel R. Rizkala - Watson Labs Inc, Morristown, NJ USADRIVE Study Grp
- Publication Details
- Journal of nephrology, v 22(4), pp 553-560
- Publisher
- Springer Nature
- Number of pages
- 8
- Grant note
- Watson Laboratories Inc Keryx Sanofi-Aventis Genzyme; Sanofi-Aventis; Genzyme Corporation Astellas; Astellas Pharmaceuticals Novartis Ortho Biotech Watson and Novaflux Technologies
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- MD (Doctor of Medicine) Program; Nephrology (and Hypertension)
- Web of Science ID
- WOS:000271853700017
- Scopus ID
- 2-s2.0-70249125464
- Other Identifier
- 991019169399504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Urology & Nephrology